# CRISPR THERAPEUTICS AG (CRSP) FY2026 Q2 Balance Sheet

- Company: CRISPR THERAPEUTICS AG (CRSP)
- Period: As of 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-03, accession number 0001193125-26-330672
- Page: https://plicit.ai/financials/crsp/fy2026-q2-balance-sheet
- Chart image: https://plicit.ai/charts/crsp-fy2026-q2-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 2,650,770,000 US dollars
- **Current assets**: 2,371,770,000 US dollars
- **Non-current assets**: 279,000,000 US dollars
- **Liabilities**: 904,219,000 US dollars
- **Current liabilities**: 132,896,000 US dollars
- **Non-current liabilities**: 771,323,000 US dollars
- **Equity**: 1,746,551,000 US dollars
- **Marketable securities**: 2,073,015,000 US dollars
- **Cash and cash equivalents**: 291,337,000 US dollars
- **Prepaid expenses and other current assets**: 7,418,000 US dollars
- **Operating lease assets**: 125,592,000 US dollars
- **Property and equipment, net**: 108,068,000 US dollars
- **Other non-current assets**: 37,711,000 US dollars
- **Restricted cash**: 7,629,000 US dollars
- **Accrued expenses**: 70,278,000 US dollars
- **Operating lease liabilities**: 18,646,000 US dollars
- **Other current liabilities**: 16,982,000 US dollars
- **Deferred revenue, current**: 15,189,000 US dollars
- **Accounts payable**: 11,307,000 US dollars
- **Accrued tax liabilities**: 494,000 US dollars
- **Long-term debt**: 586,198,000 US dollars
- **Operating lease liabilities, net of current portion**: 178,904,000 US dollars
- **Other non-current liabilities**: 6,221,000 US dollars
- **Additional paid-in capital**: 3,909,746,000 US dollars
- **Common shares, CHF 0.03 nominal value, 144,447,967 and 132,477,166 shares authorized at June 30, 2026 and December 31, 2025, respectively, 96,761,275 and 96,009,657 shares issued at June 30, 2026 and December 31, 2025, respectively, 96,660,959 and 95,894,341 shares outstanding at June 30, 2026 and December 31, 2025, respectively**: 3,130,000 US dollars
- **Accumulated deficit**: negative 2,161,636,000 US dollars
- **Accumulated other comprehensive (loss) income**: negative 4,629,000 US dollars
- **Treasury shares, at cost, 100,316 and 115,316 shares at June 30, 2026 and December 31, 2025, respectively.**: negative 60,000 US dollars
- **Gross equity (calculated)**: 3,912,876,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.